Leo Pharma has applied for expanded approval for eczema treatment in EU
At the same time as launching tralokinumab in the EU and US, Leo Pharma is also trying to expand the approved patient group for the treatment.
by mikkel aabenhus hemmingsen, translated by catherine brett
The EU Committee for Medicinal Products for Human Use (CHMP) has convened its monthly meeting, with a Danish treatment on the agenda.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EMA management board elects new chair
For subscribers
.jpg&w=384&q=75)
